GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (NAS:CORT) » Definitions » Earnings Yield (Joel Greenblatt) %

CORT (Corcept Therapeutics) Earnings Yield (Joel Greenblatt) % : 3.21% (As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Corcept Therapeutics Earnings Yield (Joel Greenblatt) %?

Corcept Therapeutics's Enterprise Value for the quarter that ended in Sep. 2024 was $4,472.1 Mil. Corcept Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $143.4 Mil. Corcept Therapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2024 was 3.21%.

The historical rank and industry rank for Corcept Therapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

CORT' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11.95   Med: 4.42   Max: 12.24
Current: 2.47

During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Corcept Therapeutics was 12.24%. The lowest was -11.95%. And the median was 4.42%.

CORT's Earnings Yield (Joel Greenblatt) % is ranked better than
85.37% of 1367 companies
in the Biotechnology industry
Industry Median: -13.74 vs CORT: 2.47

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Corcept Therapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2024 was 5.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Corcept Therapeutics Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Corcept Therapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corcept Therapeutics Earnings Yield (Joel Greenblatt) % Chart

Corcept Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.02 4.90 6.64 6.40 3.59

Corcept Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 3.59 5.52 4.37 3.21

Competitive Comparison of Corcept Therapeutics's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Corcept Therapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corcept Therapeutics's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Corcept Therapeutics's Earnings Yield (Joel Greenblatt) % falls into.



Corcept Therapeutics Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Corcept Therapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=107.282/2990.5244
=3.59 %

Corcept Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $143.4 Mil.



Corcept Therapeutics  (NAS:CORT) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Corcept Therapeutics Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Corcept Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
149 Commonwealth Drive, Menlo Park, CA, USA, 94025
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Executives
Gary Charles Robb officer: CHIEF FINANCIAL OFFICER C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph Douglas Lyon officer: Chief Accounting Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William Guyer officer: Chief Development Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Sean Maduck officer: See Remarks C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
David L Mahoney director SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Hazel Hunt officer: Chief Scientific Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph K Belanoff director, officer: CHIEF EXECUTIVE OFFICER 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Baker G Leonard Jr director, 10 percent owner 755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005
Joshua M. Murray director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Atabak Mokari officer: Chief Financial Officer 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Gillian Cannon director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gregg H Alton director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Kimberly Park director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Andreas Grauer officer: Chief Medical Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025

Corcept Therapeutics Headlines

From GuruFocus